



## vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

June 11, 2025

HIGH POINT, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of *cadisegliatin*, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the H.C. Wainwright “HCW@Home” Series, being held virtually on Thursday, June 12, 2025.

Conference details are as follows:

### H.C. Wainwright “HCW@Home with vTv Therapeutics”

Format: Fireside Chat

Moderator: Emily Bodnar, Director, H.C. Wainwright

vTv Therapeutics Speakers:

- Paul Sekhri, Chairman of the Board, President & Chief Executive Officer
- Thomas Strack, MD, Chief Medical Officer
- Carmen Valcarce, Ph.D., Executive Vice President, Chief Scientific Officer
- Michael Tung, MD, MBA, Chief Financial Officer

Date: Thursday, June 12, 2025

Time: 10:00 AM ET

Webcast Link: Register [here](#)

The webcast of the event will be accessible from News & Events page of the vTv website.

### About vTv Therapeutics

vTv Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv's clinical pipeline is led by *cadisegliatin*, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules into different indications for chronic diseases. Learn more at [vtvtherapeutics.com](http://vtvtherapeutics.com) or follow the company on [LinkedIn](#) or [X](#).

### Investor Contact

John Fraunces

LifeSci Advisors, LLC

917-355-2395

[jfraunces@lifesciadvisors.com](mailto:jfraunces@lifesciadvisors.com)

### Media Contact

Caren Begun

TellMed Strategies

201-396-8551

[caren.begun@tmstrat.com](mailto:caren.begun@tmstrat.com)



Source: vTv Therapeutics Inc.